首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1764946

2031 年歐洲生物製劑市場預測 - 區域分析 - 按產品、應用、來源和製造

Europe Biologics Market Forecast to 2031 - Regional Analysis - by Product, Application, Source, and Manufacturing

出版日期: 2025年04月14日 | 出版商:

The Insight Partners | 英文 162 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2023 年歐洲生物製劑市場價值為 1150.576 億美元，預計到 2031 年將達到 4154.684 億美元；預計 2023 年至 2031 年的複合年成長率為 17.4%。

對外包製造業務的偏好推動了歐洲生物製劑市場

生物製劑製造是一個複雜的過程，其成功取決於所有操作的正確執行和監控。製造工廠需要訓練有素、具備生物加工和製程工程技術知識的人員。對於經驗豐富的團隊來說，管理使用手動和開放式製造方法進行首次臨床試驗，並隨後建立更符合商業需求的流程可能並非易事。因此，製造商選擇與合約開發和製造組織 (CDMO) 合作，以加速其臨床研究和商業化運作。 CDMO 以合約方式為生物製劑公司提供產品開發、臨床試驗支援、製造和商業化服務。與 CDMO 合作可以為生物製劑製造商提供可擴展性和獲取技術專業知識的管道，而無需支付管理費用，同時還能加快產品上市速度並提高成本效益。 2022 年 4 月，ThermoGenesis 在美國加州建立了自己的 CDMO 工廠，為細胞和基因療法製造商提供 CDMO 服務。該公司憑藉其專業知識，專注於生產嵌合抗原受體T細胞（CAR-T細胞）、T細胞受體（TCR）、腫瘤浸潤白血球（TIL）、自然殺手細胞（NK）、誘導多能幹細胞（iPSC）和間質幹細胞（MSC）。事實證明，將生物製劑生產外包給CDMO對製造商而言具有成本效益。此外，他們還可以利用CDMO先進的技術基礎設施和專業知識。 CDMO採用適當的、規劃好的流程來生產生物製劑。因此，將生物製劑生產業務外包給CDMO的趨勢日益高漲，推動了生物製劑市場的成長。

歐洲生物製劑市場概況

歐洲的生物製劑市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。歐洲擁有第二大市場佔有率，這可以歸因於癌症負擔的增加和癌症診斷技術的進步，有助於早期發現。單株抗體在各種研發應用、癌症治療和免疫疾病中的日益廣泛使用也促進了歐洲生物製劑市場的進步。在歐盟所有國家中，德國在醫療保健研究和基礎設施方面的投資最大。根據歐盟統計局的數據，2015 年德國的醫療保健支出為 3.949 億美元，是該地區相關國家中最高的之一。根據 2015 年經合組織衛生統計數據，德國的醫療支出成長速度快於經合組織預測的實際平均值；這可能與為支持藥品開發、研究和製造而投入的資本增加有關。因此，對醫療保健產業的強勁資金支持提振了德國的生物製劑市場。

2031年歐洲生物製劑市場營收及預測（百萬美元）

歐洲生物製劑市場細分

歐洲生物製劑市場分為產品、應用、來源、製造和國家。

根據產品類型，歐洲生物製劑市場細分為單株抗體、疫苗、重組激素/蛋白質、細胞和基因療法以及其他。單株抗體在2023年佔據了最大的市場。

從應用角度來看，歐洲生物製劑市場主要分為癌症、傳染病、自體免疫疾病等。 2023年，癌症領域佔據了最大的市場。

從來源來看，歐洲生物製劑市場分為哺乳動物和微生物兩大類。 2023年，哺乳動物類生物製劑佔了更大的市場。

根據製造方式，歐洲生物製劑市場分為外包和內部製造。 2023年，外包部分佔據了更大的市場。

就國家而言，歐洲生物製劑市場分為德國、英國、義大利、法國、西班牙和歐洲其他地區。 2023年，德國佔據了歐洲生物製劑市場的主導地位。

AbbVie Inc、輝瑞公司、三星生物製品有限公司、ADMA Biologics, Inc.、無錫生物製品有限公司、Catalent Inc、AGC Biologics AS、阿斯利康公司、安進公司、Nitto Avecia 和 Quality Assistance sa 是歐洲生物製劑市場的一些領先公司。

Biologics manufacturing is a complex process whose success depends on the proper execution and monitoring of all operations. The manufacturing facilities need trained personnel with technical knowledge of bioprocessing and process engineering. Managing the attempts to reach the first clinical trial using a manual and open manufacturing method and then building a more commercially suitable process can be tricky for an experienced team. Thus, manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization operations. CDMOs provide product development, clinical trial support, manufacturing, and commercialization services to biologics companies on a contract basis. Partnering with CDMO enables scalability and access to technical expertise without overhead costs, along with higher speed to market and greater cost efficiencies for biologics manufacturers. In April 2022, ThermoGenesis established its own CDMO facility in California, US, to provide CDMO services to cell and gene therapy manufacturers. Using its expertise, the company focuses on manufacturing chimeric antigen receptor-T cell (CAR-T cell), T-cell receptor (TCR), tumor-infiltrating leukocyte (TIL), natural killer cell (NK), iPSC, and mesenchymal stem cell (MSC). Outsourcing biologics manufacturing to CDMOs proves cost-effective for manufacturers. Additionally, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing biologics. Thus, the surging preference for outsourcing biologics manufacturing operations to CDMOs fuels the biologics market growth.

Europe Biologics Market Overview

The biologics market in Europe is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe holds the second-largest market share, which can be attributed to the increasing cancer burden and technological advancements in cancer diagnostics to aid in early detection. The growing use of monoclonal antibodies in various R&D applications, cancer therapies, and immunological disorders is also contributing to the biologics market progress in Europe. Germany invests significantly in healthcare research and infrastructure among all countries in the European Union (EU). According to Eurostat, the healthcare expenditure in Germany accounted for US$ 394.9 million in 2015, which was one of the highest among the relative countries in the region. According to OECD Health Statistics 2015, health spending in Germany is growing faster than the actual OECD-predicted average; this can be associated with the higher capital investments made to support the development, research, and manufacturing of pharmaceuticals. Thus, the robust financial backing to the healthcare sector bolsters the biologics market in Germany.

Europe Biologics Market Revenue and Forecast to 2031 (US$ Million)

Europe Biologics Market Segmentation

The Europe biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Europe biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Europe biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the Europe biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Europe biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Europe biologics market is segmented into Germany, the UK, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Europe biologics market.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Europe Biologics Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Chronic Diseases
- 4.1.2 Preference for Outsourcing Manufacturing Operations
4.2 Market Restraints
- 4.2.1 High Cost of Biologics
4.3 Market Opportunities
- 4.3.1 Gene and Cell Therapy Advancements in Biologics
4.4 Future Trends
- 4.4.1 Strategic Initiatives by Companies
4.5 Impact of Drivers and Restraints:

5. Biologics Market - Europe Analysis

5.1 Europe Biologics Market Revenue (US$ Million), 2021-2031
5.2 Europe Biologics Market Forecast Analysis

6. Europe Biologics Market Analysis - by Product

6.1 Monoclonal Antibodies
- 6.1.1 Overview
- 6.1.2 Monoclonal Antibodies: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Vaccine
- 6.2.1 Overview
- 6.2.2 Vaccine: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.3 Recombinant Hormones/Proteins
- 6.3.1 Overview
- 6.3.2 Recombinant Hormones/Proteins: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.4 Cell and Gene Therapy
- 6.4.1 Overview
- 6.4.2 Cell and Gene Therapy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.5 Others
- 6.5.1 Overview
- 6.5.2 Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Europe Biologics Market Analysis - by Application

7.1 Cancer
- 7.1.1 Overview
- 7.1.2 Cancer: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Infectious Diseases
- 7.2.1 Overview
- 7.2.2 Infectious Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Autoimmune Diseases
- 7.3.1 Overview
- 7.3.2 Autoimmune Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Biologics Market Analysis - by Source

8.1 Mammalian
- 8.1.1 Overview
- 8.1.2 Mammalian: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Microbial
- 8.2.1 Overview
- 8.2.2 Microbial: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Biologics Market Analysis - by Manufacturing

9.1 Outsourced
- 9.1.1 Overview
- 9.1.2 Outsourced: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 In-house
- 9.2.1 Overview
- 9.2.2 In-house: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Biologics Market - Country Analysis

10.1 Europe
- 10.1.1 Europe Biologics Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.1 Europe Biologics Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.2 Germany: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.2.1 Germany: Europe Biologics Market Share - by Product
    - 10.1.1.2.2 Germany: Europe Biologics Market Share - by Application
    - 10.1.1.2.3 Germany: Europe Biologics Market Share - by Source
    - 10.1.1.2.4 Germany: Europe Biologics Market Share - by Manufacturing
  - 10.1.1.3 United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.3.1 United Kingdom: Europe Biologics Market Share - by Product
    - 10.1.1.3.2 United Kingdom: Europe Biologics Market Share - by Application
    - 10.1.1.3.3 United Kingdom: Europe Biologics Market Share - by Source
    - 10.1.1.3.4 United Kingdom: Europe Biologics Market Share - by Manufacturing
  - 10.1.1.4 Italy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.4.1 Italy: Europe Biologics Market Share - by Product
    - 10.1.1.4.2 Italy: Europe Biologics Market Share - by Application
    - 10.1.1.4.3 Italy: Europe Biologics Market Share - by Source
    - 10.1.1.4.4 Italy: Europe Biologics Market Share - by Manufacturing
  - 10.1.1.5 France: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.5.1 France: Europe Biologics Market Share - by Product
    - 10.1.1.5.2 France: Europe Biologics Market Share - by Application
    - 10.1.1.5.3 France: Europe Biologics Market Share - by Source
    - 10.1.1.5.4 France: Europe Biologics Market Share - by Manufacturing
  - 10.1.1.6 Spain: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.6.1 Spain: Europe Biologics Market Share - by Product
    - 10.1.1.6.2 Spain: Europe Biologics Market Share - by Application
    - 10.1.1.6.3 Spain: Europe Biologics Market Share - by Source
    - 10.1.1.6.4 Spain: Europe Biologics Market Share - by Manufacturing
  - 10.1.1.7 Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.7.1 Rest of Europe: Europe Biologics Market Share - by Product
    - 10.1.1.7.2 Rest of Europe: Europe Biologics Market Share - by Application
    - 10.1.1.7.3 Rest of Europe: Europe Biologics Market Share - by Source
    - 10.1.1.7.4 Rest of Europe: Europe Biologics Market Share - by Manufacturing

11. Industry Landscape

11.1 Overview
11.2 Market Initiative
11.3 Partnerships and Collaborations
11.4 Other Developments

12. Company Profiles

12.1 AbbVie Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Pfizer Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Samsung Biologics Co Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 ADMA Biologics, Inc.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 WuXi Biologics Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Catalent Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 AGC Biologics AS
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 AstraZeneca Plc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Amgen Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Nitto Avecia
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Quality Assistance s.a.
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments

13. Appendix

13.1 About Us

簡介目錄圖表

List Of Tables

Table 1. Europe Biologics Market Segmentation
Table 2. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Table 3. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Product
Table 4. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Application
Table 5. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Source
Table 6. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Manufacturing
Table 7. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
Table 8. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 9. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 10. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
Table 12. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 13. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 14. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
Table 16. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 17. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 18. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
Table 20. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 21. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 22. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 23. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
Table 24. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 25. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 26. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 27. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
Table 28. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 29. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 30. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 31. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing

List Of Figures

Figure 1. Europe Biologics Market Segmentation - Country
Figure 2. Europe Biologics Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Biologics Market Revenue (US$ Million), 2021-2031
Figure 5. Europe Biologics Market Share (%) - by Product (2023 and 2031)
Figure 6. Monoclonal Antibodies: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 7. Vaccine: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 8. Recombinant Hormones/Proteins: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 9. Cell and Gene Therapy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 10. Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 11. Europe Biologics Market Share (%) - by Application (2023 and 2031)
Figure 12. Cancer: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 13. Infectious Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 14. Autoimmune Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 15. Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 16. Europe Biologics Market Share (%) - by Source (2023 and 2031)
Figure 17. Mammalian: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 18. Microbial: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 19. Europe Biologics Market Share (%) - by Manufacturing (2023 and 2031)
Figure 20. Outsourced: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 21. In-house: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 22. Europe Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 23. Germany: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 24. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 25. Italy: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 26. France: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 27. Spain: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 28. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)